Last reviewed · How we verify
Paclitaxel and Sorafenib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Paclitaxel and Sorafenib (Paclitaxel and Sorafenib) — Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paclitaxel and Sorafenib TARGET | Paclitaxel and Sorafenib | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paclitaxel and Sorafenib CI watch — RSS
- Paclitaxel and Sorafenib CI watch — Atom
- Paclitaxel and Sorafenib CI watch — JSON
- Paclitaxel and Sorafenib alone — RSS
Cite this brief
Drug Landscape (2026). Paclitaxel and Sorafenib — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-and-sorafenib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab